Growth momentum Target labs expanding single-cell capabilities and automation after the Fluxion acquisition and recent software launches; position as a one-stop shop for automated patch clamp and single-cell analysis to accelerate drug discovery.

Expansion opportunities Leverage high-profile funding and acquisition activity to approach prospective customers in academia and biotech with bundled solutions that combine IonFlux automated patch clamp, BioFlux shear flow systems, and CellRaft AIR software for compliant, scalable workflows.

Regulatory readiness Highlight 21 CFR Part 11 compliant software updates to reassure pharmaceutical and CRO clients seeking validated, auditable data pipelines; tailor outreach to GxP environments and compliance-focused buyers.

Global lab footprint Capitalize on the existing global install base and milestone achievements (hundreds of labs relying on Fluxion) to encourage trials or pilots in new geographies and strengthen channel partnerships with distributors.

Financial viability Present a compelling ROI narrative using recent Series B funding and multi-product portfolio to credential reliability and long-term support, targeting budgeting cycles in mid-market biotech firms and contract research organizations.